Author Index for Volume 10

Aaronson NK, 195S
Ahmed SW, 282

Bangdiwala SI, 167
Baron JA, 153
Bayrd G, 153
Beach M, 161S
Bjornson-Benson W, 65S
Blackburn GL, 368
Blanchard J, 254
Blaufox MD, 11
Blumenstein BA, 386
Boissel J-P, 120S, 254
Borhani NO, 1S, 30S
Bristol DR, 142
Brown KM, 40S
Buring JE, 142S
Buyse ME, 187S
Buzzard IM, 368, 416
Byar DP, 129

Canner PL, 84S
Chalmers I, 426
Chlebowski RT, 368
Cohn R, 167
Cutler JA, 84S

Davis B, 11
Davis CE, 167
DCCT Research Group, 83
Dixon DO, 231
Dornseif BE, 57

Elashoff R, 368
Elias PM, 153
Enas GG, 57

Fisher M, 119S
Fleiss JL, 227, 237
Forster JL, 40S
Freedman L, 129
Freedman LS, 357

Goodman SN, 188, 209
Gøtzsche PC, 31
Goyan JE, 236S

Greenberg ER, 153
Gundert-Remy U, 231S
Guyatt GH, 407

Hasford J, 119S
Hawkins BS, 108, 211
Hawkins CM, 11
Hazard C, 167
Hemminki E, 290
Hennekens CH, 142S
Hughes MD, 209S

Insull W Jr, 368

Jaeschke R, 407
Jasperse DM, 282
Jeffery RW, 65S
Jefferys JL, 30S
Jochimsen P, 368

Klimt CR, 135S
Knatterud G, 119S, 245S
Koepcke W, 222S
Kopenen P, 290

Lachin JM, 127
Langford HG, 1S, 11
Lenfant C, 228
Lowe N, 153
Lubsen J, 151S

Mandel JS, 153
Meier P, 161S
Meinert Cl, 1S, 257S
Messerer D, 119S
Miké V, 244
Morgan TM, 234
Moussa MAA, 378

Nierenberg DN, 153
Nixon DW, 368

Oberman A, 11, 40S

Panak E, 254
Peto R, 426

Peyrieux J-C, 254
Pledger G, 97
Pocock SJ, 209S
Prineas RJ, 30S, 167
Prud'homme GJ, 84S

Rimpelä U, 290
Rockhold FW, 57

Sacks H, 254
Salsburg D, 71
Sampson CB, 57
Scanlon EF, 368
Schakel SF, 416
Schlundt DG, 30S, 65S
Schneider B, 176S
Sievert YA, 416
Simon R, 1
Singer J, 407
Skin Cancer Prevention Study Group, 153
Spencer SK, 153
Spiegelhalter DJ, 357
Stevens MM, 153
Stukel TA, 153
Sugars C, 65S
Swencionis C, 11
Sylvester R, 129

Tijssen JGP, 151S
Tonascia J, 30S, 65S

Uski A, 290

Van Natta ML, 40S
Vance JC, 153

Wassertheil-Smoller S, 11
Wei LJ, 127
Wuu J, 57
Wylie-Rosett J, 11
Wynder EL, 368

Yusuf S, 205

Zimbaldi N, 11
Zucker D, 205

0197-2456/1989/$3.50

© Elsevier Science Publishing Co., Inc. 1989
655 Avenue of the Americas, New York, New York 10010

Author Index for Volume 10

Aaronson NK, 195S
Ahmed SW, 282

Bangdiwala SI, 167
Baron JA, 153
Bayrd G, 153
Beach M, 161S
Bjornson-Benson W, 65S
Blackburn GL, 368
Blanchard J, 254
Blaufox MD, 11
Blumenstein BA, 386
Boissel J-P, 120S, 254
Borhani NO, 1S, 30S
Bristol DR, 142
Brown KM, 40S
Buring JE, 142S
Buyse ME, 187S
Buzzard IM, 368, 416
Byar DP, 129

Canner PL, 84S
Chalmers I, 426
Chlebowski RT, 368
Cohn R, 167
Cutler JA, 84S

Davis B, 11
Davis CE, 167
DCCT Research Group, 83
Dixon DO, 231
Dornseif BE, 57

Elashoff R, 368
Elias PM, 153
Enas GG, 57

Fisher M, 119S
Fleiss JL, 227, 237
Forster JL, 40S
Freedman L, 129
Freedman LS, 357

Goodman SN, 188, 209
Gøtzsche PC, 31
Goyan JE, 236S

Greenberg ER, 153
Gundert-Remy U, 231S
Guyatt GH, 407

Hasford J, 119S
Hawkins BS, 108, 211
Hawkins CM, 11
Hazard C, 167
Hemminki E, 290
Hennekens CH, 142S
Hughes MD, 209S

Insull W Jr, 368

Jaeschke R, 407
Jasperse DM, 282
Jeffery RW, 65S
Jefferys JL, 30S
Jochimsen P, 368

Klimt CR, 135S
Knatterud G, 119S, 245S
Koepcke W, 222S
Kopenen P, 290

Lachin JM, 127
Langford HG, 1S, 11
Lenfant C, 228
Lowe N, 153
Lubsen J, 151S

Mandel JS, 153
Meier P, 161S
Meinert Cl, 1S, 257S
Messerer D, 119S
Miké V, 244
Morgan TM, 234
Moussa MAA, 378

Nierenberg DN, 153
Nixon DW, 368

Oberman A, 11, 40S

Panak E, 254
Peto R, 426

Peyrieux J-C, 254
Pledger G, 97
Pocock SJ, 209S
Prineas RJ, 30S, 167
Prud'homme GJ, 84S

Rimpelä U, 290
Rockhold FW, 57

Sacks H, 254
Salsburg D, 71
Sampson CB, 57
Scanlon EF, 368
Schakel SF, 416
Schlundt DG, 30S, 65S
Schneider B, 176S
Sievert YA, 416
Simon R, 1
Singer J, 407
Skin Cancer Prevention Study Group, 153
Spencer SK, 153
Spiegelhalter DJ, 357
Stevens MM, 153
Stukel TA, 153
Sugars C, 65S
Swencionis C, 11
Sylvester R, 129

Tijssen JGP, 151S
Tonascia J, 30S, 65S

Uski A, 290

Van Natta ML, 40S
Vance JC, 153

Wassertheil-Smoller S, 11
Wei LJ, 127
Wuu J, 57
Wylie-Rosett J, 11
Wynder EL, 368

Yusuf S, 205

Zimbaldi N, 11
Zucker D, 205

0197-2456/1989/$3.50

© Elsevier Science Publishing Co., Inc. 1989
655 Avenue of the Americas, New York, New York 10010

Subject Index for Volume 10

ADHERENCE
Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial, 83

ADJUVANT BREAST CANCER
Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

BASELINE CHARACTERISTICS AND RESULTS
Baseline Characteristics in the Hypertension Prevention Trial, 40S
A Critique of Recent Research on the Two-Treatment Crossover Design, 237

BAYESIAN METHODS
Comparison of Bayesian with Group Sequential Methods for Monitoring Clinical Trials, 357

BEHAVIOR MODIFICATION
Baseline Characteristics in the Hypertension Prevention Trial, 40S
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S
Recruitment in the Hypertension Prevention Trial, 30S
Treatment in the Hypertension Prevention Trial, 65S

BIAS
Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis, 31
Practical Problems in Interim Analyses, with Particular Regard to Estimation, 209S

BLOOD PRESSURE
Baseline Characteristics in the Hypertension Prevention Trial, 40S
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S
Recruitment in the Hypertension Prevention Trial, 30S
Treatment in the Hypertension Prevention Trial, 65S

BOOK REVIEW
Designing Clinical Research: An Epidemiologic Approach ed. Hulley SB and Cummings SR, 125

BOOTSTRAP CONFIDENCE LIMITS
Using Permutation Tests and Bootstrap Confidence Limits to Analyze Repeated Events Data from Clinical Trials, 129

CARRYOVER EFFECTS
A Critique of Recent Research on the Two-Treatment Crossover Design, 237

CERTIFICATION
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S

CLASSIFICATION TREES
Analysis of Clinical Trial Outcomes: Alternative Approaches to Subgroup Analysis, 176S

CLINICAL ALERT
Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

CLINICAL TRIALS, IMPACT OF ACCEPTANCE
Varied Acceptance of Clinical Trial Results, 135S

COMBINATION DRUGS
The Role of a Placebo-Treated Control Group in Combination Drug Trials, 97

COMPLIANCE
Iron Supplementation During Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel, 290

© Elsevier Science Publishing Co., Inc. 1989
655 Avenue of the Americas, New York, New York 10010
0197-2456/1989/$3.50

CONFIGURATIONS
Designing Clinical Trials for Two-sided Multiple Comparisons with a Control, 142

CONSENSUS CONFERENCE
Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

CORONARY HEART DISEASE
Comparisons of Cause of Death Verification Methods and Costs in the Lipid Research Clinics Program Mortality Follow-up Study, 167

COVARIATES
Analysis of Clinical Trial Outcomes: Some Comments on Subgroup Analyses, 187S
Choosing Covariates in the Analysis of Clinical Trials, 161S

CROSSOVER DESIGN
A Critique of Recent Research on the Two-Treatment Crossover Design, 237

DATA MANAGEMENT
Baseline Characteristics in the Hypertension Prevention Trial, 40S
The Mid-Atlantic Oncology Program's Comparison of Two Data Collection Methods, 282
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S
The Relational Database Model and Multiple Multicenter Clinical Trials, 386

DCCT
Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial, 83

DEATHS AMONG THE ELDERLY
Comparisons of Cause of Death Verification Methods and Costs in the Lipid Research Clinics Program Mortality Follow-up Study, 167

DEMOGRAPHIC CHARACTERISTICS
Baseline Characteristics in the Hypertension Prevention Trial, 40S

DIET THERAPY
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S
Maintenance of a Nutrient Database for Clinical Trials, 416
Treatment in the Hypertension Prevention Trial, 65S

DIETARY FAT
Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

DIETARY TRIAL
Baseline Characteristics in the Hypertension Prevention Trial, 40S
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S
Recruitment in the Hypertension Prevention Trial, 30S
Treatment in the Hypertension Prevention Trial, 65S

DOUBLE-BLIND
Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis, 31

DRUG REGULATION
The Role of Clinical Trials in Drug Regulation, 231S

ENROLLMENT
Recruitment in the Hypertension Prevention Trial, 30S

ESTIMATION
Practical Problems in Interim Analyses, with Particular Regard to Estimation, 209S

ETHICS
Philosophers Assess Randomized Clinical Trials: The Need for Dialogue, 244

EVIDENCE
Meta-analysis and Evidence, 188
Philosophers Assess Randomized Clinical Trials: The Need for Dialogue, 244

FACTORIAL DESIGNS
The Role of a Placebo-Treated Control Group in Combination Drug Trials, 97

FEASIBILITY
Iron Supplementation During

Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel, 290

GROUP SEQUENTIAL DESIGN AND METHODS
Analyses of Group Sequential Clinical Trials, 222S
Comparison of Bayesian with Group Sequential Methods for Monitoring Clinical Trials, 357
Exact, Conditional, and Predictive Power in Planning Clinical Trials, 378
Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry, 57

GROUP THERAPY
Treatment in the Hypertension Prevention Trial, 65S

HYPERTENSION
Baseline Characteristics in the Hypertension Prevention Trial, 40S
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S
Recruitment in the Hypertension Prevention Trial, 30S
Treatment in the Hypertension Prevention Trial, 65S
Trial of Antihypertensive Interventions and Management, 11

INFORMED CONSENT
Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial, 83

INTERACTIONS
Analysis of Clinical Trial Outcomes: Alternative Approaches to Subgroup Analysis, 176S
Analysis of Clinical Trial Outcomes: Some Comments on Subgroup Analyses, 187S
The Role of a Placebo-Treated Control Group in Combination Drug Trials, 97

INTERIM ANALYSES
Analyses of Group Sequential Clinical Trials, 222S
Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry, 57
Practical Problems in Interim Analyses, with Particular Regard to Estimation, 209S

INTERVENTION TRIAL
Baseline Characteristics in the Hypertension Prevention Trial, 40S
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S
Treatment in the Hypertension Prevention Trial, 65S

IRON PROPHYLAXIS
Iron Supplementation During Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel, 290

LIKELIHOOD
Meta-analysis and Evidence, 188

MEASUREMENT
Measurement of Health Status: Ascertaining the Minimal Clinically Important Difference, 407

META-ANALYSIS
Considerations for the Meta-analysis of Randomized Clinical Trials: Summary of a Panel Discussion, 254
Meta-analysis and Evidence, 188
Meta-analysis: Science or Religion, 257S
Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis, 31
Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

MONITORING
Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry, 57
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S

MONTE CARLO STUDY
Choosing Covariates in the Analysis of Clinical Trials, 161S

MULTIPLE COMPARISONS
Designing Clinical Trials for Two-sided Multiple Comparisons with a Control, 142

MULTIPLE TRIALS
The Relational Database Model and Multiple Multicenter Clinical Trials, 386

NONSTEROIDAL ANTIINFLAMMATORY DRUGS
Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis, 31

NOSOLOGICAL CLASSIFICATION
Comparisons of Cause of Death Verification Methods and Costs in the Lipid Research Clinics Program Mortality Follow-up Study, 167

NUTRIENT CALCULATION
Maintenance of a Nutrient Database for Clinical Trials, 416
Treatment in the Hypertension Prevention Trial, 65S

NUTRIENT DATABASE
Maintenance of a Nutrient Database for Clinical Trials, 416

NUTRITION AND CANCER
Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary, 368

OBSERVER AGREEMENT CHART
Comparisons of Cause of Death Verification Methods and Costs in the Lipid Research Clinics Program Mortality Follow-up Study, 167

ONCOLOGY GROUP
The Relational Database Model and Multiple Multicenter Clinical Trials, 386

OPTIMIZATION
Optimal Two-Stage Designs for Phase II Clinical Trials, 1

***P* VALUES**
Meta-analysis and Evidence, 188

PARTICIPANT EDUCATION
Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial, 83

PERMUTATION TEST
Using Permutation Tests and Bootstrap Confidence Limits to Analyze Repeated Events Data from Clinical Trials, 129

PHARMACEUTICAL INDUSTRY
Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry, 57

PHASE II TRIALS
Optimal Two-Stage Designs for Phase II Clinical Trials, 1
Use of Restricted Significance Tests in Clinical Trials: Beyond the One- Versus Two-Tailed Controversy, 71

PILOT STUDIES
Thrombolysis in Myocardial Infarction (TIMI) Randomized Studies Versus TIMI Open Label Studies, 245S

PLACEBO
Iron Supplementation During Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel, 290

POOLING
Meta-analysis and Evidence, 188

POWER
Analysis of Clinical Trial Outcomes: Alternative Approaches to Subgroup Analysis, 176S
Exact, Conditional, and Predictive Power in Planning Clinical Trials, 378

PRE-RANDOMIZATION
Iron Supplementation During Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel, 290

PRESCRIPTION PRACTICES
Impact of Randomized Clinical Trials on Medical Practices, 120S

PRIMARY PREVENTION TRIAL
Baseline Characteristics in the Hypertension Prevention Trial, 40S
Design, Methods, and Rationale in the Hypertension Prevention Trial, 1S
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S
Recruitment in the Hypertension Prevention Trial, 30S
Treatment in the Hypertension Prevention Trial, 65S

PRIOR DISTRIBUTION
Exact, Conditional, and Predictive

Power in Planning Clinical Trials, 378

PROGNOSTIC FACTOR
Analysis of Clinical Trial Outcomes: Some Comments on Subgroup Analyses, 187S

PROTOCOLS
Large Trials with Simple Protocols: Indications and Contraindications, 151S

QUALITY CONTROL
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S

QUALITY OF LIFE
Measurement of Health Status: Ascertaining the Minimal Clinically Important Difference, 407
Quality of Life Assessment in Clinical Trials: Methodologic Issues, 195S

RANDOMIZATION TEST
Using Permutation Tests and Bootstrap Confidence Limits to Analyze Repeated Events Data from Clinical Trials, 129

RANDOMIZED CLINICAL TRIALS
Impact of Randomized Clinical Trials on Medical Practices, 120S
Methodologic Considerations in the Design and Conduct of Randomized Trials: The U.S. Physicians' Health Study, 142S

RATIO
Meta-analysis and Evidence, 188

RECRUITMENT
Recruitment in the Hypertension Prevention Trial, 30S

RELATIONAL MODEL
The Relational Database Model and Multiple Multicenter Clinical Trials, 386

REPEATED EVENTS
Using Permutation Tests and Bootstrap Confidence Limits to Analyze Repeated Events Data from Clinical Trials, 129

RESPONSIVENESS
Measurement of Health Status: Ascertaining the Minimal Clinically Important Difference, 407

RHEUMATOID ARTHRITIS
Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis, 31

ROUTINE HEALTH SERVICES
Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial, 83

SAMPLE SIZE
Recruitment in the Hypertension Prevention Trial, 30S

SELECTION PROCEDURES
Choosing Covariates in the Analysis of Clinical Trials, 161S
Recruitment in the Hypertension Prevention Trial, 30S

SIGNIFICANCE TESTS
Use of Restricted Significance Tests in Clinical Trials: Beyond the One- Versus Two-Tailed Controversy, 71

SITE VISITS
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S

SKIN CANCER PREVENTION STUDY
The Skin Cancer Prevention Study: Design of a Clinical Trial of Beta-Carotene Among Persons at High Risk for Nonmelanoma Skin Cancer, 153

STATISTICAL INFERENCE
Considerations for the Meta-analysis of Randomized Clinical Trials: Summary of a Panel Discussion, 254
Meta-analysis and Evidence, 188
Philosophers Assess Randomized Clinical Trials: The Need for Dialogue, 244

STOPPING RULES
Analyses of Group Sequential Clinical Trials, 222S
Comparison of Bayesian with Group Sequential Methods for Monitoring Clinical Trials, 357
Practical Problems in Interim Analyses, with Particular Regard to Estimation, 209S

STROKE
The "Trials" of a Long-Term Clinical Trial: The Ticlopidine Aspirin Stroke Study and the Canadian–American Ticlopidine Study, 236S

STUDY SIZE
Large Trials with Simple Protocols: Indications and Contraindications, 151S

SUBGROUP ANALYSIS
Analysis of Clinical Trial Outcomes: Alternative Approaches to Subgroup Analysis, 176S
Analysis of Clinical Trial Outcomes: Some Comments on Subgroup Analyses, 187S

SUPPORT CURVES
Meta-analysis and Evidence, 188

TICLOPIDINE
The "Trials" of a Long-Term Clinical Trial: The Ticlopidine Aspirin Stroke Study and the Canadian–American Ticlopidine Study, 236S

TIMI
Thrombolysis in Myocardial Infarction (TIMI) Randomized Studies Versus TIMI Open Label Studies, 245S

TRAINING
Quality Assurance and Monitoring in the Hypertension Prevention Trial, 84S